Literature DB >> 9690453

Stimulation of immune suppressive CD34+ cells from normal bone marrow by Lewis lung carcinoma tumors.

M A Wright1, K Wiers, K Vellody, D Djordjevic, M R Young.   

Abstract

Progressive growth of metastatic Lewis lung carcinoma (LLC-LN7) tumors is associated with increased levels of bone-marrow-derived CD34+ cells having natural suppressor (NS) activity toward T cells. The present studies determined whether tumor-derived products are responsible for this induction of NS activity. Culturing normal bone marrow cells with LLC-LN7-conditioned medium (LLC-CM) or with recombinant granulocyte/macrophage-colony-stimulating factor (GM-CSF) resulted in the appearance of NS activity. The development of NS activity coincided with a prominent increase in the levels of CD34+ cells. That the CD34+ cells were responsible for the NS activity of the bone marrow cultures containing LLC-CM was shown by the loss of NS activity when CD34+ cells were depleted. The stimulation of CD34+ NS cells by LLC-CM was attributed to tumor production of GM-CSF, since neutralization of GM-CSF within the LLC-CM reduced its capacity to increase CD34+ cell levels. Studies also showed that the induction of CD34+ NS cells by LLC-CM and GM-CSF could be overcome by including in the cultures an inducer of myeloid differentiation, 1alpha,25-dihydroxyvitamin D3 [1,25(OH)2D3]. These results demonstrate that the mechanism by which the LLC-LN7 tumors stimulate increased levels of CD34+ NS cells from normal bone marrow is by their production of GM-CSF and that this can be blocked with the myeloid differentiation inducer 1,25(OH)2D3.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9690453     DOI: 10.1007/s002620050485

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  7 in total

Review 1.  Hampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancer.

Authors:  Sabrin Husein Albeituni; Chuanlin Ding; Jun Yan
Journal:  Cancer J       Date:  2013 Nov-Dec       Impact factor: 3.360

2.  Chemoattraction of femoral CD34+ progenitor cells by tumor-derived vascular endothelial cell growth factor.

Authors:  M R Young; K Kolesiak; M A Wright; D I Gabrilovich
Journal:  Clin Exp Metastasis       Date:  1999       Impact factor: 5.150

3.  Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function.

Authors:  Ping-Ying Pan; George X Wang; Bingjiao Yin; Junko Ozao; Teresa Ku; Celia M Divino; Shu-Hsia Chen
Journal:  Blood       Date:  2007-09-20       Impact factor: 22.113

4.  1α, 25 Dihydroxyvitamin D (1,25(OH)2D) inhibits the T cell suppressive function of myeloid derived suppressor cells (MDSC).

Authors:  J C Fleet; G N Burcham; R D Calvert; B D Elzey; T L Ratliff
Journal:  J Steroid Biochem Mol Biol       Date:  2019-11-26       Impact factor: 4.292

5.  Implication of stem cells in the biology and therapy of head and neck cancer.

Authors:  Barbara Wollenberg
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2012-04-26

Review 6.  Reviewing the Significance of Vitamin D Substitution in Monoclonal Gammopathies.

Authors:  Vanessa Innao; Alessandro Allegra; Lia Ginaldi; Giovanni Pioggia; Massimo De Martinis; Caterina Musolino; Sebastiano Gangemi
Journal:  Int J Mol Sci       Date:  2021-05-06       Impact factor: 5.923

Review 7.  Epigenetics in myeloid derived suppressor cells: a sheathed sword towards cancer.

Authors:  Chao Zhang; Shuo Wang; Yufeng Liu; Cheng Yang
Journal:  Oncotarget       Date:  2016-08-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.